Interestingly, they found that several treatments, in particular fingolimod, can induce the expression of CTLA-4 and that its higher expression or function could contribute to reducing the responses of autoreactive T cells and to inhibiting autoimmune diseases, such as MS [86]. This evidence concerns the gene CTLA4 and myeloid sarcoma.